Analytical Characterization Platforms in Drug Development: Proteomics and Mass Spectrometry

Genomics tells us what might happen; proteomics and mass spec tell us what is actually happening, and how to measure it. Analytical characterization in drug development has become one of the most technically demanding disciplines in the biopharmaceutical industry, as therapeutic pipelines shift toward increasingly complex molecules, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and viral vectors. High-resolution mass spectrometry (MS) and high-throughput proteomics platforms now underpin workflows across every stage of development, from initial target identification through to clinical quality control. The analytical question has evolved from "what is in this sample?" to "does this molecule behave as expected under every condition regulators will examine?"

Mass spectrometry and proteomics platforms for analytical characterization

Mass spectrometry and proteomics platforms together form the analytical backbone of modern drug development, covering activities from early target identification through to regulatory filing. As reviewed in a 2024 editorial in Frontiers in Medicine, MS has become a pivotal tool for the identification and characterization of proteins and peptides across clinical applications, moving well beyond its origins as a purely research-grade technique. Continued advances in instrumentation and data analysis now allow thousands of proteins to be measured in a single sample with high sensitivity and in a highly standardized manner.

The core instrumentation categories span high-resolution discovery platforms, targeted quantification systems, and intact mass analyzers, each suited to different stages and question types across the drug development workflow.

Table 1. Mass spectrometry platform types, their primary analytical modes, and typical applications across the drug development workflow.

Selecting the right platform depends on the characterization question being asked, the required dynamic range, and the regulatory context in which results will be used.

For biologic therapeutics, the analytical scope is especially demanding. More than 90% of drug candidates fail between Phase I and approval, and detailed molecular characterization using high-resolution MS is increasingly central to making earlier, better-informed go/no-go decisions. The ability to assess binding interactions, structural stability, and post-translational modification (PTM) profiles at the molecular level is changing how development teams prioritize candidates before substantial clinical investment is made.

High-throughput proteomics in drug target identification and biomarker discovery

High-throughput proteomics has become a primary engine of drug target identification, enabling researchers to analyze thousands of proteins simultaneously and map their expression, interactions, and modifications across disease states. A 2025 review in the Journal of Medicinal Chemistry describes MS-based proteomics as a disruptive platform that enables comprehensive analysis of protein expression, interactions, and modifications, far surpassing the capabilities of traditional single-protein methods, with ongoing progress in data acquisition and AI-assisted analysis further enhancing throughput.

Acquisition strategy strongly influences the quality and scalability of proteomic data, and the choice between data-dependent and data-independent approaches has significant downstream consequences for reproducibility and clinical utility.

Table 2. Comparison of data-dependent acquisition (DDA) and data-independent acquisition (DIA) proteomics across key workflow parameters.

DIA is increasingly the preferred approach in translational settings where reproducibility across hundreds of clinical samples is non-negotiable, though DDA retains value in early-stage discovery where broad, unbiased coverage takes priority over quantitative consistency.

Proteomics also extends into toxicoproteomics, where broad protein profiling characterizes adverse responses to candidate compounds during development. Identifying off-target binding and downstream pathway activation provides a more mechanistic picture of compound liabilities than traditional biochemical assays, supporting more informed attrition decisions before costly in vivo studies.

Mass spectrometry in CMC development: from cell line to lot release

Mass spectrometry supports every stage of CMC development for biologic drug products, from cell line characterization through upstream bioprocessing, downstream purification, formulation, and final lot release. MS contributes to upstream expression analysis, downstream purification monitoring, formulation development, critical quality attribute characterization, and comparability studies, making it one of the few analytical tools with genuine utility at every stage of the biologics development lifecycle. A grounding in bioprocessing fundamentals and bioreactor operations is inseparable from the design of analytical systems needed to verify molecule quality at each stage.

The accurate measurement of intact masses by modern high-resolution instruments enables primary structure confirmation, including sequence verification and disulfide bond mapping. For complex modalities such as ADCs, where structural heterogeneity arising from variable drug-to-antibody ratio distributions complicates characterization, MS provides information that conventional immunoassay methods cannot reliably deliver. Advanced MS technologies enable label-free, high-resolution characterization and quantification of emerging biotherapeutics with enhanced speed and sensitivity, with ion mobility integration now further improving selectivity in complex matrices.

Mass spectrometry workflows in cell and gene therapy extend these capabilities to host cell protein clearance verification, where LC-MS/MS workflows identify residual process-derived impurities at a level of resolution that enzyme-linked immunosorbent assay methods cannot achieve. LC-MS/MS-based approaches have become central to demonstrating adequate impurity clearance in viral vector products, where the complexity of the host cell proteome demands more sensitive and specific detection than traditional immunoassay-based methods can provide.

Proteogenomics in drug development: linking genomic data to protein quantification

Proteogenomics links genomic sequencing data to protein quantification workflows, giving drug development teams a more complete picture of which candidate targets are genuinely dysregulated at the protein level rather than simply altered at the genomic level. Genomic alterations do not always produce functional effects at the protein level, meaning that target selection based on sequencing data alone can overestimate the biological relevance of a given mutation. In oncology specifically, proteogenomic studies have shown that combining sequencing data with proteomic analyses enables teams to prioritize targets that are both genetically altered and dysregulated at the protein level, increasing the likelihood of clinical success by building biological validation into the earliest stages of the pipeline.

The practical challenge in proteogenomics lies in bioinformatics infrastructure: integrating large-scale MS datasets with genomic variant databases requires computational pipelines that many laboratories are still building. Advances in spectral library construction and database search algorithms are reducing the barrier to entry, but the depth of proteogenomic analysis achievable still varies significantly between well-resourced discovery organizations and smaller development-stage companies. The analytical instrumentation is increasingly capable; the bottleneck is frequently the data analysis layer and the investment required to build it.

The emergence of multiomics integration, combining proteomic data with transcriptomic, metabolomic, and genomic layers, is extending the interrogation of drug mechanisms beyond what any single platform can address. These approaches are described in a 2025 review in Discover Applied Sciences as having transformed drug development by enabling precision medicine and targeted therapies grounded in a deeper understanding of disease biology.

Native mass spectrometry for structural characterization of complex biologics

Native mass spectrometry enables structural characterization of intact protein complexes by preserving non-covalent interactions during ionization, producing assembly-state and conformational data that denatured-state approaches cannot access. A 2025 publication in RSC Medicinal Chemistry describes native MS as an increasingly important biophysical tool as therapeutic modalities diversify, noting growing need for routine characterization of biomolecular targets and their noncovalent interactions to guide contemporary drug discovery.

Cell and Gene Therapies: The Evolution of Advanced Biologics

This eBook takes a look at the challenges shaping advanced biologics, alongside practical strategies to improve consistency, scalability, and compliance across development and manufacturing.

View eBook

Advertisement

For bispecific antibodies, multi-domain fusion proteins, and ADCs, native MS provides assembly-state information that is critical for understanding molecular behavior in biological matrices. The technique can capture binary and ternary complexes within a single experiment, making it particularly valuable for characterizing mechanisms of action that depend on multi-component interaction networks. For analytical release testing of viral vectors, including AAV and lentiviral vector quality control, native MS and intact mass photometry approaches are increasingly applied to full/empty capsid ratio determination, providing quantitative information that complements traditional ultracentrifugation-based methods.

Hydrogen-deuterium exchange MS (HDX-MS) adds a complementary layer of structural information by mapping protein dynamics and solvent accessibility, informing both formulation stability assessments and epitope characterization for biologic-target interaction studies. Together, native MS and HDX-MS are moving from specialist research applications toward routine deployment in CMC analytical packages, driven by regulatory expectations for deeper structural understanding of complex biologic candidates and by the practical reality that understanding a molecule's behavior in solution is increasingly a prerequisite for successful formulation development.

Standardizing and automating mass spectrometry workflows for clinical-scale proteomics

Standardizing mass spectrometry workflows for clinical-scale proteomics is one of the most persistent operational challenges in translational drug development. Method validation under ICH Q2(R2) is a prerequisite for assay data to be accepted in regulatory submissions, requiring demonstration of specificity, linearity, accuracy, precision, and robustness under conditions relevant to the intended clinical application. The challenge is compounded by the inherent complexity of proteomics workflows, where sample preparation variability, instrument drift, and database search parameter choices can all introduce systematic biases that only become apparent at the scale of clinical cohort studies.

Automation has become an enabling prerequisite for scaling these workflows. A 2024 study in Chemical Science demonstrated a fully automated proteomics sample preparation platform achieving greater than 94% digestion efficiency and greater than 98% labeling efficiency across 87 samples, with high intra- and inter-batch reproducibility. The impact of automation on sample preparation for mass spectrometry is measurable not only in throughput but in the reduction of human variability that has historically been the primary source of irreproducibility in discovery proteomics workflows, where manual pipetting steps introduce coefficients of variation that can obscure real biological signal.

Instrument front-end technologies including automated sample injection systems are further compressing cycle times, enabling analytical labs to process hundreds of samples per day without compromising data quality. Integrating process analytical technology into the broader analytical development strategy ensures that the quality insights generated by MS platforms feed directly into the process control decisions that shape manufacturing outcomes.

Regulatory expectations for analytical characterization of biologic drug products

Regulatory expectations for analytical characterization of biologic drug products have risen substantially over the past decade, and expectations continue to increase as complex new modalities enter clinical development. For mAbs, ADCs, and biosimilars, ICH Q6B defines the MS-based characterization requirements that analytical development teams must satisfy prior to regulatory submission, covering primary sequence confirmation, glycan profiling, lot comparability assessment, and product-related impurity and variant characterization. For viral vectors in gene therapy, guidance from the FDA and EMA is evolving rapidly, with expectations for characterization depth increasing with each new product approval as regulators build a clearer picture of what constitutes adequate quality assurance for complex gene medicines.

The strategic challenge facing analytical development teams is no longer primarily instrumentation: it is building the validated methods, qualified personnel, appropriate reference standards, and robust data management infrastructure needed to deploy these platforms in a regulated context. The analytical characterization infrastructure built during development is ultimately what determines whether a biologic can be manufactured consistently and defended credibly at regulatory inspection.

This content includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.